IQVIA Holdings Inc. - IQV STOCK NEWS

IQVIA Holdings (NYSE:IQV) announced that CFO Ron Bruehlman will participate in a virtual fireside chat at the William Blair Growth Stock Conference on June 2, 2021, at 10:20 a.m. EDT. Investors can access the live audio webcast on the IQVIA Investor Relations website, with a replay available later that day. IQVIA is a global leader in analytics and clinical research, employing around 72,000 people across over 100 countries. The company focuses on enhancing patient privacy while delivering insights to improve healthcare outcomes through its innovative solutions.

The IQVIA Institute for Human Data Science released a report highlighting resilience in R&D activity despite COVID-19 disruptions in 2020. The report notes a 43% growth in the late-stage oncology drug pipeline since 2015, alongside a record 66 new drug approvals. Clinical trial productivity slightly increased but remains low due to trial complexity. R&D funding remained strong, unaffected by the pandemic, indicating robust strategic investments across the industry.

On May 11, 2021, Veeva Systems issued a statement countering IQVIA's misleading press release regarding an e-discovery ruling in their ongoing antitrust case. Veeva asserts that the ruling does not resolve key issues and is appealing it. All of Veeva's claims are proceeding to trial, which is expected to start in early 2023. Additionally, an investigation by the FTC into IQVIA's alleged anti-competitive practices is ongoing, highlighting concerns about IQVIA's data monopoly in the life sciences sector.

IQVIA (NYSE:IQV) recently won a significant legal battle against Veeva Systems (NYSE:VEEV) in the U.S. District Court of New Jersey. The court sanctioned Veeva multiple times for engaging in the destruction of evidence and covering up its wrongdoings, including the misappropriation of IQVIA's intellectual property. The ruling includes limitations on the use of evidence at trial and an award for legal fees. IQVIA expressed satisfaction with the decision, highlighting Veeva's deceitful practices and reinforcing the need for intellectual property protection.

IQVIA announced a collaboration with Corium, Inc. to support the launch of AZSTARYS™, a new treatment for ADHD approved by the FDA on March 2, 2021. This collaboration aims to enhance market engagement and streamline commercialization efforts. IQVIA will utilize its technology, analytics, and field services to connect healthcare professionals with Corium’s ADHD expertise. The partnership promises efficient engagement, leveraging IQVIA's Orchestrated Customer Engagement platform to maximize outreach. This initiative marks a significant step in providing effective treatment options for patients aged six and older.

IQVIA announced its innovative approach, Connected Intelligence, aimed at enhancing insights and decision-making in the life sciences sector. This strategy integrates IQVIA’s extensive healthcare data, advanced analytics, and technologies to facilitate faster drug development. Key initiatives include:

• Accelerating over 350 clinical research studies for COVID-19.
• Supporting 60 decentralized clinical trials in 40 countries.
• Linking real-world data for disease understanding and drug discovery.

IQVIA aims to improve societal health outcomes through innovation and significant investments in the healthcare ecosystem.

IQVIA Holdings Inc. reported a strong first quarter of 2021 with revenues of $3,409 million, marking a 23.8% increase year-over-year. Technology & Analytics Solutions revenue grew by 20.7%, while Research & Development Solutions surged by 29.6%. The company's backlog reached $23.2 billion, with expectations to convert approximately $6.5 billion to revenue in the next year. Adjusted EBITDA rose to $744 million, up 32.4%. As a result, IQVIA raised its full-year guidance for revenue and earnings per share, projecting significant growth driven by continued demand in life sciences.

IQVIA Holdings Inc. (NYSE:IQV) will release its first-quarter 2021 financial results on April 22, 2021, before the market opens. A conference call and webcast led by the management team will take place at 9:00 a.m. ET on the same day. Investors can access the earnings release on the IQVIA Investor Relations website. IQVIA is a global leader in analytics and technology solutions for the life sciences industry, employing approximately 70,000 individuals across 100 countries.